Skip to main content
SpringerLink
Log in

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

  • Pediatric Hypertension (JT Flynn, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular importance, published recently, have been highlighted as: •• Of major importance

  1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.

    Article  Google Scholar 

  2. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.

    Article  PubMed  CAS  Google Scholar 

  3. •• The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, Pediatrics 2011, 128 (Supplement 5): S213–S256. Updated, comprehensive cardiovascular risk reduction guidelines; hypertension section similar to the Fourth Report.

  4. Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci. 2010;119:151–61.

    Article  PubMed  Google Scholar 

  5. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20:791–7.

    Article  PubMed  Google Scholar 

  6. Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics. 2007;119:e538–43.

    Article  PubMed  Google Scholar 

  7. Stewart JN, McGillivray D, Sussman J, Foster B. The value of routine blood pressure measurement in children presenting to the emergency department with nonurgent problems. J Pediatr. 2008;153:478–83.

    Article  PubMed  Google Scholar 

  8. Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol. 2009;24:1939–49.

    Article  PubMed  Google Scholar 

  9. Batisky DL. Obesity and the role of lifestyle and dietary intervention in the management of pediatric hypertension. J Med Liban. 2010;58:171–4.

    PubMed  Google Scholar 

  10. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24:1101–12.

    Article  PubMed  Google Scholar 

  11. Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605–12.

    Article  PubMed  Google Scholar 

  12. Flynn JT, Falkner BE. Obesity hypertension in adolescents: epidemiology, evaluation, and management. J Clin Hypertens. 2011;13:323–31.

    Article  Google Scholar 

  13. Batisky DL. Blood pressure variability, prehypertension, and hypertension in adolescents. Adolesc Health, Med Ther. 2012;3:1–8.

    Google Scholar 

  14. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289:2560–72.

    Article  PubMed  CAS  Google Scholar 

  15. •• Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90. Only recent clinical trial in pediatric hypertension comparing two different classes of agents.

    Article  PubMed  CAS  Google Scholar 

  16. Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiologic parameters. Med Hypoth. 2010;75:439–41.

    Article  Google Scholar 

  17. Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173–7.

    Article  PubMed  CAS  Google Scholar 

  18. Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin-Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24:1164–80.

    Article  PubMed  CAS  Google Scholar 

  19. Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58:111–20.

    Article  PubMed  CAS  Google Scholar 

  20. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330–55.

    Article  CAS  Google Scholar 

  21. Flynn JT, Newburger JW, Daniels SW, et al. for the PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.

    Article  PubMed  CAS  Google Scholar 

  22. •• Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14:383–7. This reference is a concise, well-organized, and current review of this topic.

    Article  CAS  Google Scholar 

  23. Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990–6.

    Article  PubMed  CAS  Google Scholar 

  24. Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76.

    Article  PubMed  Google Scholar 

  25. •• Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Anti-hypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens. 2012;14:388–95. Demonstrates ongoing use of antihypertensive medications despite lack of FDA-approved pediatric labeling.

    Article  Google Scholar 

Download references

Disclosure

D. Batisky: research funding from Novartis and Takeda (NIH R01HL098332-01A1).

Author information

Authors and Affiliations

  1. Department of Pediatrics, Emory University School of Medicine, 1648 Pierce Drive Northeast, Atlanta, GA, 30322, USA

    Donald L. Batisky

  2. Pediatric Hypertension Program, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA, 30322, USA

    Donald L. Batisky

  3. Emory-Children’s Center, 2015 Uppergate Drive NE, Atlanta, GA, 30322, USA

    Donald L. Batisky

Authors
  1. Donald L. Batisky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald L. Batisky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batisky, D.L. What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?. Curr Hypertens Rep 14, 603–607 (2012). https://doi.org/10.1007/s11906-012-0302-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-012-0302-7

Keywords

Search

Navigation